On the Record · Royalty Pharma

Royalty Pharma acquisitions, on the record

The businesses Royalty Pharma bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Karuna Word for word“(3) In December 2023, Bristol Myers Squibb announced it has agreed to acquire Karuna.” 10-K for 2023	agreed acquisition	December 2023	—
MorphoSys Word for word“(4) In February 2024, Novartis announced it has entered into an agreement to acquire MorphoSys.” 10-K for 2023	agreed acquisition	February 2024	—
Roche's Evrysdi royalties Word for word“In October 2023, we acquired additional royalties on Roche’s Evrysdi for an upfront payment of $1 billion.” 10-K for 2023	acquisition	October 2023	$1 billion
Skytrofa royalty interest Word for word“In September 2023, we acquired a royalty interest in Skytrofa for an upfront payment of $150 million.” 10-K for 2023	acquisition	September 2023	$150 million
Adstiladrin royalty interest Word for word“In August 2023, we acquired a royalty interest in Adstiladrin for an upfront payment of $300 million and a $200 million additional milestone payment contingent on certain manufacturing goals.” 10-K for 2023	acquisition	August 2023	—
ecopipam royalty interest Word for word“(2) We acquired an interest in ecopipam in January 2024.” 10-K for 2023	acquisition	January 2024	—
the Manager (RP Management, LLC) via RP LLC membership interests Word for word“In January 2025, we agreed to acquire the Manager for approximately $1.1 billion in total consideration (the “Internalization”).” 10-K for 2024	agreed acquisition	January 2025	approximately $1.1 billion
Rytelo royalty from Geron Corporation Word for word“In November 2024, we acquired a synthetic royalty on Rytelo from Geron Corporation for an upfront payment of $125 million.” 10-K for 2024	acquisition	In November 2024	$125 million
Niktimvo royalty from Syndax Pharmaceuticals, Inc. Word for word“In November 2024, we acquired a synthetic royalty on Niktimvo from Syndax Pharmaceuticals, Inc. for an upfront payment of $350 million.” 10-K for 2024	acquisition	In November 2024	$350 million
Yorvipath royalty from Ascendis Pharma A/S Word for word“In September 2024, we acquired a synthetic royalty on Yorvipath from Ascendis Pharma A/S for an upfront payment of $150 million.” 10-K for 2024	acquisition	In September 2024	$150 million
Voranigo royalty interest from Agios Pharmaceuticals Word for word“In May 2024, we announced a transaction to acquire a royalty interest in Voranigo from Agios Pharmaceuticals for an upfront payment of $905 million contingent on FDA approval.” 10-K for 2024	acquisition	—	$905 million
RP Manager (the former external manager) Word for word“We completed the acquisition of RP Manager on May 16, 2025.” 10-K for 2025	acquisition	May 16, 2025	—
MorphoSys Development Funding Bonds Word for word“In 2025, we generated $3.3 billion of Portfolio Receipts (as defined below) which does not include the $511 million of proceeds from our sale of the MorphoSys Development Funding Bonds.” 10-K for 2025	divestiture	—	$511 million

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)
2023-12-31	$0
2024-12-31	$0
2025-12-31	$74.4 million

Deal filings since 2016

2026-05-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-09-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-05-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-05-19 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2025-04-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-01-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-12-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-06-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-06-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-12-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-07-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-07-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-11-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-09-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-06-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from Royalty Pharma’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-11. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.